Shagun Singh: Great. Any color on cadence through the year on sales and margins? Thanks.
Thomas Sandgaard: I would expect it — obviously, we had a little higher comps this year as, again, the sales force continues to do better. But as far as order growth, I think we’re looking at mid-20 growth, and I think we see that across most of the quarters. I don’t think it’s going to jump around too much. So it should be a little steadier this year than it was in the prior year, and that, again, should drive that approximately 20% revenue growth. And don’t forget, right now, the forecast is EPS going from what would have been $0.40 this year to $0.50, so over a 25% increase in kind of pro forma EPS year-to-year.
Shagun Singh: Thank you.
Operator: Thank you. Your next question is from Yi Chen from H.C. Wainwright. Please ask your question.
Yi Chen: Thank you for taking my questions. Regarding the 23% expected growth in 2024, out of that, how much will be primarily driven by NexWave. Can you comment on that?
Thomas Sandgaard: Please go ahead, Mr. Don..
Donald Gregg: Yes. I would say that we don’t expect the growth to slow down on the NexWave. So let’s assume that is in the 20% range. We are pushing hard to see revenue growth from all the other products that we are selling through our sales force. And that’s probably where the majority of this is going to come from. So all those other products will hopefully double in terms of orders and therefore, get us up to more than 25% order growth and again, spilling over to what we expect to be a 23% growth in revenue.
Yi Chen: So NexWave is — will still be the main growth driver for — within 2024, correct?
Donald Gregg: Well, clearly, we’ll get that one below 50%, while we really grow the orders. But the chances are that it will still be a little over 50% as we exit the year. And long term, we are hoping to have a much more diversified product portfolio also in the pain management division.
Yi Chen: Got it. Got it. And I’m also curious, are there any attractive opportunity out there that the company could look at that may involve a fast-growing products on the market Zynex could potentially acquire versus using the existing cash to buy back more shares.?
Donald Gregg: We are evaluating about a handful of those that are exactly making products that we either sell or similar to what we sell right now would be a great complement and also in a price range where we could afford it. We have not initiated any negotiating, but we’re getting pretty good in our research there.
Yi Chen: Got it. Thank you.
Operator: Thank you. There are no further questions at this time. I will now hand the call back to Thomas and go ahead for the closing remarks.
Thomas Sandgaard: Well, thank you for joining us today. We’re pleased with our performance this quarter and the consistent growth our team is delivering. We look forward to leveraging that momentum throughout the rest of the year and speaking to you in upcoming investor events. We appreciate your time and interest in Zynex and have a great day.
Operator: Thank you — ladies and gentlemen, the conference has now ended. Thank you all for joining. You may all disconnect.
